Qlife Holding AB (QLIFE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qlife Holding AB (QLIFE) has a cash flow conversion efficiency ratio of 0.196x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.47 Million ≈ $-158.63K USD) by net assets (Skr-7.51 Million ≈ $-807.98K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Qlife Holding AB - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Qlife Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read QLIFE current and long-term liabilities for a breakdown of total debt and financial obligations.
Qlife Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qlife Holding AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Real Estate Credit Investments Limited
LSE:RECI
|
-0.049x |
|
Chatham Rock Phosphate Ltd
V:NZP
|
-0.023x |
|
TFP Solutions Bhd
KLSE:0145
|
-0.142x |
|
RevoluGROUP Canada Inc
V:REVO
|
-0.399x |
|
Victorian Plumbing Group PLC
LSE:VIC
|
0.226x |
|
Comanche International Public Company Limited
BK:COMAN
|
-0.055x |
|
iCoreConnect Inc. Common stock
NASDAQ:ICCT
|
0.083x |
|
COLLPLANT BIOTECH. IS-01
F:CPT
|
N/A |
Annual Cash Flow Conversion Efficiency for Qlife Holding AB (2019–2025)
The table below shows the annual cash flow conversion efficiency of Qlife Holding AB from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see QLIFE market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-7.51 Million ≈ $-807.98K |
Skr-15.60 Million ≈ $-1.68 Million |
2.077x | -92.06% |
| 2024-12-31 | Skr-1.43 Million ≈ $-153.78K |
Skr-37.37 Million ≈ $-4.02 Million |
26.151x | +1346.70% |
| 2023-12-31 | Skr-23.12 Million ≈ $-2.49 Million |
Skr-41.80 Million ≈ $-4.50 Million |
1.808x | +445.18% |
| 2022-12-31 | Skr91.15 Million ≈ $9.81 Million |
Skr-47.73 Million ≈ $-5.14 Million |
-0.524x | -228.02% |
| 2021-12-31 | Skr163.18 Million ≈ $17.56 Million |
Skr-26.05 Million ≈ $-2.80 Million |
-0.160x | +15.05% |
| 2020-12-31 | Skr89.55 Million ≈ $9.64 Million |
Skr-16.83 Million ≈ $-1.81 Million |
-0.188x | -202.62% |
| 2019-12-31 | Skr62.48 Million ≈ $6.72 Million |
Skr-3.88 Million ≈ $-417.54K |
-0.062x | -- |
About Qlife Holding AB
Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents in Sweden. The company offers Egoo.Health Platform, a product platform that enables advanced biomarker testing, consisting of a small device, disposable capsules, and the supplementing software. Its biomarkers include CRP/C-reactive protein, procalcitonin, Nt-pro-BNP, lipids, HbA1c/D-vit… Read more